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Ethnic Disparities in Conditional Survival of Patients with
Non-small Cell Lung Cancer
Samuel J. Wang, MD, PhD,* C. David Fuller, MD,† and Charles R. Thomas Jr., MD*
Purpose: Conditional survival (CS) is an accurate estimate of
survival probability for patients who have already survived at least
1 year after diagnosis. The purpose of this study was to determine
whether ethnicity plays a role in 5-year CS rates for patients with
non-small cell lung cancer (NSCLC).
Materials and Methods: Using the Surveillance, Epidemiology,
and End Results database, we analyzed 96,480 patients with NSCLC
diagnosed between 1988 and 1995. Patients were divided into five
ethnic groups: White (non-Hispanic), Hispanic, African American,
Asian/Pacific Islander, and Native American/Alaskan. Using the life
table method, we computed observed 5-year CS rates for patients
who had already survived up to 5 years after diagnosis. Results were
analyzed by stage, age, sex, and histology.
Results: In general, 5-year CS rates increase for all ethnicities as
time from diagnosis increases, but African Americans continued to
have lower CS rates compared with other ethnic groups, even up to
5 years from diagnosis. When analyzed by stage, Hispanics with
stage IV disease showed the greatest improvement in CS rate,
increasing to 73% at 5 years from diagnosis. Among patients older
than 70 years, African Americans had the lowest CS at 5 years—
only 28%, compared with 40% to 47% for other groups. When
analyzed by histology, Hispanics with large cell carcinoma had the
worst CS rate (35% at 5 years).
Conclusion: For patients with NSCLC surviving a period of time
after diagnosis, 5-year CS rates vary by ethnicity. CS can provide
accurate prognostic information for patients with NSCLC who have
already survived several years after diagnosis.
Key Words: Survival, Ethnicity, Race, Lung cancer, Non-small cell
lung cancer.
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Survival estimates for patients with cancer are most oftenreported in the literature only as survival from the time of
diagnosis. Survival probability changes, however, for patients
who survive a period of time after diagnosis. Estimates of
survival probability made at the time of diagnosis are less
meaningful for patients who have already survived at least 1
year. Conditional survival (CS) is an accurate estimate of
survival probability for patients who have survived at least 1
year after diagnosis.1 It is taken from the concept of condi-
tional probability and accounts for the fact that hazard rates
can change over time.
The concept of CS has important practical clinical
value to both clinicians and patients.1,2 This information
would allow the clinician to more accurately answer the
question of a patient’s current prognosis, given that he or she
has already survived a period of time since diagnosis and
treatment. If the CS of a patient with cancer has increased
enough to essentially match the expected survival of the
general population, it allows a more objective basis to deem
a patient “cured” of the disease. By relaying information
about changing risk over time, CS could also be used in
helping to determine the appropriate frequency of follow-up
visits and aggressiveness of surveillance testing based on the
patient’s current risk profile.
Several authors have previously published studies on
CS for various disease sites, including breast,3 colon,4 central
nervous system,5,6 lung,7,8 and other advanced carcinomas.9
We have also previously presented our work on CS for
various disease sites at several national meetings.10–22
In recent years, there has been greater awareness about
ethnic disparities in cancer diagnosis, treatment, and progno-
sis. In 2003, the Agency for Healthcare Research and Quality
(AHRQ) published its first annual National Healthcare Dis-
parities Report,23 which highlighted the differences in access
and use of health care services among various ethnicities and
socioeconomic groups. The purpose of this study was to
determine the effect of ethnicity in the CS of patients with
non-small cell lung cancer (NSCLC).
METHODS
Definition of Conditional Survival
CS is derived from the concept of conditional proba-
bility in biostatistics. CS can be calculated from traditional
actuarial or life table survival data. The mathematical defini-
tion of CS can be expressed as follows:
Let S(t) be traditional life table survival at time t.
Conditional survival, CS(y  x), is the probability of surviving
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y years, given that the person has already survived x years.
Conditional survival can be expressed as:
CS y  x
S x y
S x
For example, to compute the 5-year CS for a patient
who has already survived 2 years, take the life table survival
at 5  2 years, S(7) and divide this by the life table survival
at 2 years, S(2). As patients survive longer periods of time
after diagnosis, changes in their CS are a reflection of the
variation in hazard rate over time. This can be depicted
graphically by examining how the slope of the traditional life
table curve changes over time (Figure 1).
Data Analysis
The Surveillance, Epidemiology, and End Results
(SEER) Program2 from the National Cancer Institute is a
population-based cancer registry covering approximately
26% of the United States population across several disparate
geographic regions. When compared with the total United
FIGURE 1. Change in hazard rate
in a typical actuarial life table sur-
vival curve leading to change in
conditional survival. The instanta-
neous hazard rate can be repre-
sented by the slope of the survival
curve. At point A (Year 1), the slope
is greater than at point B (Year 6),
indicating a higher hazard rate at
Year 1 compared with Year 6. This
change in slope leads to a relative
increase in conditional survival. The
5-year conditional survival after 1
year is the survival at point B di-
vided by the survival at point A:
S6/S1  0.115/0.399  0.288.
TABLE 1. Selected Characteristics of NSCLC Patients Diagnosed Between 1988 and
1995 (N  96,480). Abbreviations: PI  Pacific Islander, AL  Alaskan Native.
White Hispanic Black Asian/PI Native Am/AL
Stage
I 17,068 (22) 659 (19) 2,026 (18) 864 (19) 85 (23)
II 3,333 (4) 114 (3) 372 (3) 197 (4) 14 (4)
III 19,884 (26) 952 (28) 3,339 (30) 1,404 (30) 115 (31)
IV 25,597 (33) 1,190 (35) 4,074 (37) 1,549 (34) 107 (29)
Unknown 11,075 (14) 483 (14) 1,341 (12) 591 (13) 47 (13)
Sex
Male 45,909 (60) 2,053 (60) 7,408 (66) 3,006 (65) 237 (64)
Female 31,048 (40) 1,345 (40) 3,744 (34) 1,599 (35) 131 (36)
Age
Age 70 yrs 41,301 (54) 1,939 (57) 7,677 (69) 2,477 (54) 239 (65)
Age 70 yrs 35,656 (46) 1,459 (43) 3,475 (31) 2,128 (46) 129 (35)
Histology
Squamous Cell 20,886 (27) 833 (25) 3,408 (31) 1,089 (24) 112 (30)
Adenocarcinoma 30,064 (39) 1,372 (40) 3,976 (36) 2,186 (47) 128 (35)
Large Cell 8,038 (10) 350 (10) 1,280 (11) 413 (9) 34 (9)
Other/Unknown 17,969 (23) 843 (25) 2,488 (22) 917 (20) 94 (26)
Totals 76,957 (100) 3,398 (100) 11,152 (100) 4,605 (100) 368 (100)
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FIGURE 2. Ten-year overall survival
for all patients with non-small cell
lung cancer, grouped by ethnicity.
FIGURE 3. Five-year conditional
survival for all patients with non-
small cell lung cancer, grouped by
ethnicity.
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States population of various ethnic groups as per the 2000
United States Census, SEER coverage includes 23% of all
African Americans in the United States, 40% of Hispanics,
42% of Native Americans and Alaska Natives, 53% of
Asians, and 70% of Hawaiian/Pacific Islanders. SEER pro-
gram registries collect data on patient demographics, cancer
type and site, stage, first course of treatment, and follow-up
vital status. The SEER Program obtains fairly accurate and
complete mortality data by collecting information on all
deaths occurring in the United States from the National
Center for Health Statistics on an annual basis.
Using the April 2005 release of the SEER 13 data-
base,24 we analyzed survival data from all patients diagnosed
with NSCLC between 1988 and 1995. Patients were limited
to those diagnosed after 1988 because this was the earliest
year that SEER cases were staged with American Joint
Committee on Cancer (AJCC) tumor, node, metastasis stag-
ing.25 Cases diagnosed up to 1995 were included to ensure at
least 7 years of follow-up data (through December 2002).
Cases were not included in the analysis if they were only
identified by death certificate or autopsy, and only cases in
which NSCLC was the first primary tumor were included.
To examine the effect of ethnicity on CS, all patients
were categorized into the following five ethnic groups, based
on the SEER Race Recode B variable24: Caucasian (non-
Hispanic), Hispanic, African American, Asian/Pacific Is-
FIGURE 4. Five-year conditional survival
for patients with non-small cell lung can-
cer, by stage and ethnicity. *Results sup-
pressed for small groups in which the
standard error was 10%.
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lander (including Japanese, Chinese, Filipino, and Hawaiian),
and Native American/Alaskan Native.
Patients who had squamous cell carcinoma, adenocar-
cinoma, large cell carcinoma, or any other unknown or
undifferentiated carcinoma (excluding small cell carcinomas,
sarcomas, or lymphomas) were included. Classification of
NSCLC histologies by ICD-O-3 code was as follows: squa-
mous cell (8052, 8070–8079), adenocarcinoma (8140–8149,
8250–8269, 8310, 8323, 8480–8481, 8550–8579), large cell
(8012–8015, 8020–8029), and other/unknown (8000–8011,
8016–8019, 8030–8051, 8053–8069, 8080–8139, 8150–
8249, 8270–8309, 8311–8322, 8324–8479, 8482–8549).
Using the SEER*Stat26 software with the actuarial life
table method, we computed relative 5-year CS as the proba-
bility of surviving an additional 5 years after a patient had
already survived from 0 to 5 years after diagnosis. We
computed relative 5-year CS by ethnicity and analyzed results
by AJCC stage, age 70 years, sex, and histology. All CS
rates are reported as relative survival, defined as the observed
survival rate divided by the expected survival rate for similar
individuals matched on age, sex, ethnicity, and date at which
the age was coded. Expected survival rates were taken from
the SEER United States Expanded Races (1970, 1980) ex-
pected rate table. Relative survival analyses are often per-
FIGURE 4. Continued.
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formed to account for competing causes in SEER analyses
because cause of death information is often incomplete or
unknown.
RESULTS
A total of 96,480 patients with NSCLC met the inclu-
sion criteria and were included in this analysis. Patient char-
acteristics by ethnicity are shown in Table 1. When grouped
by race, 76,957 (80%) patients were Caucasian (White, non-
Hispanic); 3,398 (4%) were Hispanic; 11,152 (12%) were
African American; 4,605 (5%) were Asian or Pacific Is-
lander; and 368 (0.4%) were Native American or Alaskan
Natives. Patients were further divided by stage, sex, age, and
histology.
The traditional actuarial life table 10-year overall sur-
vival plot, grouped by ethnicity, is shown in Figure 2. These
10-year survival data were used to calculate the 5-year CS
rates shown in Figures 3 to 7. Error bars depict the standard
error for each CS statistic. Results were suppressed if the
standard error was greater than 10%.
African American patients had lower CS rates com-
pared with other ethnic groups, even up to 5 years from
diagnosis (Figure 3). When analyzed by stage (Figure 4),
Native Americans/Alaskan Natives with stage I disease ini-
FIGURE 5. Five-year conditional survival
for patients with non-small cell lung can-
cer, by sex and ethnicity. *Results sup-
pressed for small groups in which the
standard error was 10%.
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tially had lower CS rates compared with the other groups,
although this difference diminished as time progressed since
diagnosis. Hispanics with stage IV disease showed the great-
est improvement in CS rate, increasing to 73% at 5 years
since diagnosis, compared with 39% to 56% for other ethnic
groups. When examined by sex (Figure 5), there was no
noticeable difference among ethnic groups. Among patients
older than 70 years of age (Figure 6), African Americans had
the lowest CS rates, initially increasing to 33% by year 4 but
then decreasing to 28% by year 5. When analyzed histolog-
ically (Figure 7), African Americans with squamous cell
carcinoma had lower CS rates than Whites or Hispanics, but
this difference was not as noticeable for patients with adeno-
carcinoma. Hispanics with large cell carcinoma had the worst
CS rate (35% at 5 years).
DISCUSSION
CS offers several advantages over more commonly
reported static survival statistics, such as 5-year overall sur-
vival. By describing changing risk over time, it conceptually
reiterates the truism that patient risk is not static. This
information is potentially of great interest to both patients and
clinicians. For patients who are being seen in the follow-up
FIGURE 6. Five-year conditional survival
for patients with non-small cell lung can-
cer, by age and ethnicity. *Results sup-
pressed for small groups in which the
standard error was 10%.
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clinic several years after their initial diagnosis, these CS
tables can be used to more accurately portray their current
prognosis. Psychologically, the ability of patients to more
accurately conceptualize their changing risk profile may be of
great benefit. Clinicians can also use CS data to implement
more evidence-driven approaches to post-therapy surveil-
lance. For instance, many physicians taper scheduled fol-
low-up after 3 to 5 years, often with little justification based
on survival data. More complete assessment of the changing
profile of patient risk over time using CS provides an avenue
to more cogently determine optimal intervals for follow-up
visits and surveillance testing.
Additionally, CS can be used to detect differentials in
population survival patterns. For instance, crude 5-year DSS
does not account for the fact that the vast majority of
mortality risk may fall earlier or later in the span of time
assessed. Like Kaplan-Meier graphs, CS rates provide a ready
mechanism to assess differential temporal risk of mortality in
a given population.
Using the SEER dataset represents an effort to deter-
mine CS parameters based on large population cohorts. It
should be noted, however, that increased cohort size comes at
the cost of treatment homogeneity. The SEER dataset, while
geographically limited, represents the best large-scale pool of
FIGURE 7. Five-year conditional sur-
vival for patients with non-small cell
lung cancer, by histology and ethnicity.
*Results suppressed for small groups in
which the standard error was 10%.
Journal of Thoracic Oncology • Volume 2, Number 3, March 2007 Ethnic Disparities in Conditional Survival for NSCLC
Copyright © 2007 by the International Association for the Study of Lung Cancer 187
patient data, and allows us to make reasonable estimates of
CS rates that are broadly applicable for the general United
States population.
CS in lung cancer has been previously explored in other
series,7,8 although the application of ethnicity as a covariate
has not been previously reported. Compared with these prior
studies, our overall CS results are consistent with those of
both Merrill et al.,7 who used an earlier version of the SEER
database, and Skuladottir et al.,8 who analyzed patients from
the Danish Cancer Registry. Perhaps not surprisingly, Merrill
et al.’s results most closely correspond to our results for
White patients because Whites account for 80% of patients in
SEER.
That ethnic populations exhibit survival differentials
has been established in numerous series.27–38 Similar to our
study, several of these investigators29,31,35,36 have also found
that African Americans have worse survival at diagnosis
compared with other ethnicities. Our study also shows that,
whereas CS generally improves over time for most groups of
patients, African Americans often continue to have worse CS
rates compared with Whites up to 5 years after diagnosis,
particularly in earlier stage disease, male patients, age 70
FIGURE 7. Continued.
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years, and squamous cell histology. For patients with ad-
vanced stage disease or large cell histology or who were
female, however, the CS rate for African Americans shows
greater improvement over time and actually exceeds that of
Whites as time elapses from diagnosis.
In most subsets, we found that the Native American/
Alaskan Native group had the poorest initial survival but
generally showed a large improvement in CS over time.
Hispanics seemed to do relatively well in stage IV disease but
relatively poorly if they had large cell histology. However,
the numerical paucity of patients in these ethnic subgroups
and the incumbent statistical uncertainty thereof precludes
ready comparison with the much larger ethnic categories
reported.
To determine whether the apparent ethnic differences in
CS could be explained solely by differences in other con-
founding factors, we performed a multivariable regression
analysis to simultaneously control for other covariates. We
constructed a series of Cox proportional hazard models (JMP
6 Software, Cary, NC) on subsets of the survival data 1 to 5
years after initial diagnosis, using covariates of stage, age
65 years, sex, histology, and race to determine the inde-
pendent contribution of race to differentials in CS. In this
multivariate analysis, we found that the effect likelihood ratio
for the race category was statistically significant for every
year after diagnosis, except for year 5. Although the actual
risk ratio between any two races varied in statistical signifi-
cance from year to year, this analysis showed that race is still
an independent prognostic factor for CS at least 4 years after
diagnosis. Our findings are consistent with what others have
found regarding the independent contribution of race on
survival using the SEER database.32,33
Whether ethnic disparities in lung cancer mortality are
truly caused by genetic differences among races or are simply
a surrogate marker of differing access to care because of
socioeconomic differences is still a matter of debate.29,31,34–36
In any case, using CS data in combination with ethnicity
allows better assessment of patients’ risk in follow-up after
they have survived several years after diagnosis.
As in other studies of CS, patients with advanced stage
disease and poorer initial prognoses have the greatest in-
creases in CS as they survive for longer periods of time from
diagnosis.3,5,7,8 The rapid increase in CS for advanced disease
may have useful clinical application. For patients with stage
IV disease who survive 3 years from diagnosis, subsequent
mortality outcomes are comparable to those of patients with
stage I disease at diagnosis. Consequently, if one follows-up
patients with stage I disease for x years, patients with stage IV
disease should be similarly followed for x  3 years. Using
this type of CS information can allow optimal follow-up
testing frequency and duration to be based on a patient’s
actual disease risk, rather than simply on custom or tradition.
The SEER Race Recode B variable was used to deter-
mine ethnicity. SEER uses medical records and registration
information to determine all races, except for Hispanic, which
is determined by surname. Whereas the designation of Whites
and African Americans in SEER has been studied and found
to be reliable,39 the designation for other ethnicities has not
been externally validated, so its accuracy is unknown. It has
been hypothesized that the use of surnames to determine His-
panic race may result in misclassification of more women than
men because of marital name changes; nevertheless, preliminary
studies indicate that the race variables in SEER are still likely
more accurate than those in Medicare databases.39
Throughout this analysis, relative survival rates, de-
fined as observed survival divided by the expected survival
for that patient, are reported. Because cause of death infor-
mation is often unreliable in the SEER database,40 relative
survival is a useful alternative measure that assesses the
proportion of excess deaths that occur among patients with
lung cancer compared with the general population. It serves
to adjust for differences in observed survival that may be the
result of competing causes of death.2 Expected survival rates
were obtained from the SEER 1970, 1980 Expanded Races
expected rate table by matching patients by age, sex, race,
and the date at which age was coded.
It is imperative for physicians to more specifically
characterize, use, and communicate patient risk profiles as
accurately as possible. Models such as Adjuvant! Online41 or
MSKCC risk nomograms42–46 are especially inviting as a
mechanism for initial risk stratification. Incorporation of a CS
component would allow patients and physicians to re-evalu-
ate the patient’s risk as it changes over time, which would
potentially afford more accurate management of disease as a
part of the physician’s surveillance algorithm. Similarly,
ethnicity, which is a key component of risk stratification at
diagnosis, should be implemented as a covariate in CS-based
analyses.
Finally, efforts must be made to successfully commu-
nicate this changing risk profile to the patient, an often
difficult task for the oncologist. When patients that are seen in
follow-up inquire about their current prognosis, they should
be given an accurate risk assessment that accounts for the
time already survived since diagnosis.
We have found that CS in lung cancer varies by
ethnicity, and these data can provide more accurate prognos-
tic information for patients who have already survived several
years since diagnosis.
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